A randomized phase II study of UFT/LV or TEGAFOX for patient with curatively resected high risk Stage II and Stage III colorectal cancer.
Not Applicable
- Conditions
- high risk stage II/ stage III colorectal cancer
- Registration Number
- JPRN-UMIN000007696
- Lead Sponsor
- Chiba surgical oncology development association
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1) Serious diarrea 2) Serious postoperative complications 3) Serious drug hypersensitivity 4) Pregnant or nursing 5) Serious coexisting illness 1; diabetes mellitus, uncontrolled or controlled with insulin 2; uncontrolled hypertension 3; liver cirrhosis 4; renal disfaunction 5; severe pulmonary dysfunction 6; active infection 7; history of myocardial infarction, unstable angina within 6 months prior to the registration 6) Active synchronous or metachronous malignancy other than carcinoma in situ 7) Sensory neuropathy 8) Severe mental disorders 9) Not suitable for participating in the study for any other reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 3-year desiese free survival rate
- Secondary Outcome Measures
Name Time Method